BioCryst Pharmaceuticals (NASDAQ: BCRX) surged 8.5% to $7.03 after the company reported that it has selected two optimized plasma kallikrein inhibitors for hereditary angioedema into preclinical development. Share volume was 715,000, compared to an all-day average of 998,000
